Novel Aza-podophyllotoxin Derivative Inhibits Growth of Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with high recurrence and metastasis rates.
• Existing treatments for early-stage TNBC often fail, leading to disease progression.
• Novel therapeutic strategies are urgently needed to combat TNBC.

Purpose of the Study:

• To identify and characterize a novel small molecule, CET022, for its potential therapeutic efficacy against TNBC.
• To elucidate the molecular mechanisms underlying CET022's anti-cancer effects in TNBC.

Main Methods:

• In vitro studies using multiple TNBC cell lines (MDA-MB-231, MDA-MB-468, 4T1, EMT6).
• Assessment of cell growth, clonogenic potential, cell-cycle progression, and apoptosis.
• Proteomic analysis to identify molecular targets of CET022.

Main Results:

• CET022 demonstrated significant inhibition of TNBC cell growth and clonogenic potential in vitro.
• CET022 treatment induced G2/M phase cell-cycle arrest and apoptosis in TNBC cells.
• Proteomic analysis revealed that CET022 targets metabolic pathways, specifically reducing Enolase-3 levels.

Conclusions:

• CET022 is a promising novel small molecule inhibitor of TNBC growth and survival.
• The drug's mechanism involves targeting glycolysis by reducing Enolase-3, a key metabolic enzyme.
• These findings provide a strong foundation for the clinical development of CET022 for TNBC treatment.